International Journal of Nanomedicine · 2018 · 37 citations · 41 references
PharmacyPharmaceuticsPharmacologyCancer PharmacologyDrug DeliveryNanoparticle Drug DeliveryCancer Drug DeliveryDrug EncapsulationIntracellular Drug DeliveryLipid-based Drug Delivery SystemsNanocarriers For TherapeuticsNanomaterials For Drug DeliveryDrug Delivery NanocarriersIntracellular Drug DistributionLipid NanomaterialsLipid Nanoparticle Delivery SystemsLipid NanoparticlesLipid-based Drug CarriersNanocarrier Encapsulation EfficiencyPeptide-based Drug Carriers
BACKGROUND: To facilitate selective and enhanced drug delivery to hepsin (Hpn)-expressing cancer cells, RIPL peptide (IPLVVPLRRRRRRRRC, 16-mer)-conjugated nanostructured lipid carriers (RIPL-NLCs) were developed. METHODS: NLCs were prepared using a solvent emulsification-evaporation method and the RIPL peptide was conjugated to the maleimide-derivatized NLCs via the thiol-maleimide reaction. Employing a fluorescent probe (DiI), in vitro target-selective intracellular uptake behaviors were observed using fluorescence microscopy and flow cytometry. Separately, docetaxel (DTX) was encapsulated by pre-loading technique, then cytotoxicity and drug release were evaluated. In vivo antitumor efficacy was investigated in BALB/c nude mice with SKOV3 cell tumors after intratumoral injections of different DTX formulations at a dose equivalent to 10 mg/kg DTX. RESULTS: RIPL-NLCs showed positively charged nanodispersion, whereas NLCs were negatively charged. DTX was successfully encapsulated with an encapsulation efficiency and drug loading capacity of 95-98% and 44-46 µg/mg, respectively. DTX release was diffusion-controlled, revealing the best fit to the Higuchi equation. Cellular uptake of DiI-loaded RIPL-NLCs was 8.3- and 6.2-fold higher than that of DiI-loaded NLCs, in Hpn(+) SKOV3 and LNCaP cells, respectively. The translocation of RIPL-NLCs into SKOV3 cells was time-dependent with internalization within 1 h and distribution throughout the cytoplasm after 2 h. DTX-loaded RIPL-NLCs (DTX-RIPL-NLCs) revealed dose-dependent in vitro cytotoxicity, while drug-free formulations were non-cytotoxic. In SKOV3-bearing xenograft mouse model, DTX-RIPL-NLCs significantly inhibited tumor growth: the inhibition ratios of the DTX solution-treated and DTX-RIPL-NLC-treated groups were 61.4% and 91.2%, respectively, compared to those of the saline-treated group (control). CONCLUSION: RIPL-NLCs are good candidates for Hpn-selective drug targeting with a high loading capacity of hydrophobic drug molecules.
41
Nanostructured lipid carriers (NLC) in cosmetic dermal products☆
Robert Müller, Rejane Petersen, A. Hommoss et al. · Advanced Drug Delivery Reviews · 2007 · 686 citations
Pharmacy, Dermatology, Pharmaceutics +14